Holen Sie sich die Stockscreener-App
39.36
8.34%
3.03
Handel nachbörslich:
39.89
0.53
+1.35%
Schlusskurs vom Vortag:
$36.33
Offen:
$36.75
24-Stunden-Volumen:
625.78K
Relative Volume:
1.70
Marktkapitalisierung:
$1.12B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.47M
KGV:
-7.032
EPS:
-5.5973
Netto-Cashflow:
$-73.92M
1W Leistung:
+30.46%
1M Leistung:
+13.46%
6M Leistung:
+55.70%
1J Leistung:
+69.87%
1-Tages-Spanne:
$35.92
$39.39
1-Wochen-Bereich:
$30.55
$40.95
52-Wochen-Spanne:
$16.54
$40.95
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Vergleichen Sie LENZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
39.36 | 1.11B | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-18 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
Does LENZ Therapeutics Inc. qualify in momentum factor screeningStop Loss & Weekly High Return Opportunities - Newser
LENZ Therapeutics Inc.’s volatility index tracking explainedRate Hike & Verified Chart Pattern Signals - Newser
What the charts say about LENZ Therapeutics Inc. todayJuly 2025 Levels & Risk Managed Investment Signals - Newser
Momentum Screeners Rank LENZ Therapeutics Inc. in Top 5 TodayAI Forecast for Trending Stocks Indicates Upside - beatles.ru
What earnings revisions data tells us about LENZ Therapeutics Inc.Portfolio Safety Metrics and Return Analysis - Newser
What MACD signals say about LENZ Therapeutics Inc.Free Low Risk Picks for Daily Trading - Newser
How to manage a losing position in LENZ Therapeutics Inc.AI Powered Stock Trend Prediction Model - Newser
LENZ Therapeutics Scores Relative Strength Rating Upgrade - Investor's Business Daily
Will LENZ Therapeutics Inc. bounce back from current supportRisk-Managed Swing Setup and Signal Analysis - Newser
LENZ Therapeutics: Evaluate Stock Surge - timothysykes.com
LENZ Therapeutics Soars 11.6% on Explosive Intraday Rally: Technical Breakout or Speculative Surge? - AInvest
LENZ Therapeutics Soars 17.33% on FDA Approval, Strategic Partnership - AInvest
LENZ Therapeutics Inc. Breaks Losing Streak — Is the Trend ReversingEarly Entry Picks Before News Breakout Reviewed - beatles.ru
Using data models to predict LENZ Therapeutics Inc. stock movementFree Entry Alert With Low Drawdown Strategy - Newser
LENZ Therapeutics Surges 8% — What’s Behind the Intraday Move? - AInvest
Using R and stats models for LENZ Therapeutics Inc. forecastingEarly Entry Ideas with Momentum Potential - Newser
A Quick Look at Today's Ratings for LENZ Therapeutics(LENZ.US), With a Forecast Between $40 to $60 - 富途牛牛
Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye Drops - TipRanks
LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright By Investing.com - Investing.com South Africa
LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright - Investing.com Nigeria
FDA Approves VIZZ Eye Drops to Treat Presbyopia - Medscape
Lenz Therapeutics price target raised to $53 from $44 at BofA - TipRanks
What are LENZ Therapeutics Inc. company’s key revenue driversMaximize gains with timely market signals - Jammu Links News
How many analysts rate LENZ Therapeutics Inc. as a “Buy”Phenomenal wealth increase - Jammu Links News
What analysts say about LENZ Therapeutics Inc. stockRecord-setting profit potential - Jammu Links News
When is LENZ Therapeutics Inc. stock expected to show significant growthGet real-time alerts on high-potential stocks - Jammu Links News
What are the latest earnings results for LENZ Therapeutics Inc.Free Expert Stock Watchlist - Jammu Links News
Is LENZ Therapeutics Inc. a good long term investmentStrong return on assets - jammulinksnews.com
LENZ Therapeutics Inc. Stock Analysis and ForecastMaximize returns with expert trading insights - Jammu Links News
What is the dividend policy of LENZ Therapeutics Inc. stockHigh-octane investment gains - Jammu Links News
What catalysts could drive LENZ Therapeutics Inc. stock higher in 2025Achieve superior returns with professional insights - Jammu Links News
What is the risk reward ratio of investing in LENZ Therapeutics Inc. stockConsistently outstanding ROI - jammulinksnews.com
How volatile is LENZ Therapeutics Inc. stock compared to the marketLightning-fast growth - Jammu Links News
Why is LENZ Therapeutics Inc. stock attracting strong analyst attentionAchieve consistent returns with proven methods - Jammu Links News
Volume spikes in LENZ Therapeutics Inc. stock – what they meanFree Real Time Alerts Based on AI Prediction - Newser
LENZ Therapeutics (NASDAQ:LENZ) Sees Unusually-High Trading Volume After Analyst Upgrade - Defense World
Is it time to cut losses on LENZ Therapeutics Inc.Free Step-by-Step Stock Investment Guide - Newser
William Blair Expects Weaker Earnings for LENZ Therapeutics - Defense World
Published on: 2025-08-01 19:39:34 - Newser
Citi maintains Buy rating on LENZ Therapeutics, raises PT to $52 from $49. - AInvest
LENZ Therapeutics announces FDA Approval of VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia - Eyes On Eyecare
FDA approves LENZ Therapeutics' VIZZ for presbyopia - Eyes On Eyecare
H.C. Wainwright Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Raises Target Price to $56 - 富途牛牛
Eyes on the prize: FDA approves Lenz’s drops for presbyopia - BioWorld MedTech
LENZ Therapeutics' Eye Drop Scores First FDA Approval… - inkl
LENZ Therapeutics gets FDA nod for presbyopia eye drop (LENZ) - Seeking Alpha
LENZ Therapeutics Stock Soars 12.5% on FDA Approval of VIZZ - AInvest
Analysts Are Bullish on These Healthcare Stocks: LENZ Therapeutics (LENZ), GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
LENZ Therapeutics Says FDA Approved Eye Drop to Treat Loss of Near Vision - MarketScreener
Applying big data sentiment scoring on LENZ Therapeutics Inc.Free Risk-Adjusted Picks With Exit Strategy - Newser
LENZ Therapeutics Announces FDA Approval of VIZZ for Treatment of Presbyopia - VisionMonday.com
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lenz Therapeutics Inc-Aktie (LENZ) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L. | 10% Owner |
Jun 27 '25 |
Sale |
30.46 |
200,000 |
6,093,000 |
1,767,275 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 20 '25 |
Sale |
30.25 |
133,924 |
4,051,201 |
1,967,275 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 20 '25 |
Sale |
30.35 |
100,877 |
3,061,617 |
1,047,912 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 18 '25 |
Sale |
29.95 |
100,000 |
2,995,000 |
1,148,789 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 10 '25 |
Sale |
29.00 |
350,000 |
10,150,000 |
1,248,789 |
| Olsson Shawn | Chief Commercial Officer |
Apr 09 '25 |
Option Exercise |
2.08 |
1,400 |
2,912 |
4,733 |
| Schimmelpennink Evert B. | President, CEO and Secretary |
Mar 07 '25 |
Option Exercise |
1.04 |
4,200 |
4,368 |
49,200 |
| Olsson Shawn | Chief Commercial Officer |
Dec 16 '24 |
Option Exercise |
2.08 |
3,333 |
6,933 |
3,333 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):